Effect of Glucose-Insulin-Potassium on patients with Acute ST-Segment-Elevation Myocardial Infarction

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138804302210N1

Enrollment

Registered

2010-06-06

Start date

2008-09-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with ST elevation myocardial infarction. Acute myocardial infarction

Interventions

Intervention 1: Insulin Potassium Glucose ( 25% glucose, 50 IU of soluble insulin per liter, and 80 mmol of potassium chloride per liter) infused at 1.5 ml/kg/hour to GIK group in addition to 1.5 MU

Treatment - Drugs

Placebo

Insulin Potassium Glucose ( 25% glucose, 50 IU of soluble insulin per liter, and 80 mmol of potassium chloride per liter) infused at 1.5 ml/kg/hour to GIK group in addition to 1.5 MU of streptokinase

1 L normal saline at 60 mL/h in addition to streptokinase(1.5 MU in 30-60 minuts) infused to control group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion:All consecutive patients who had 20 minutes chest pain or its equivalent, time from symptom onset 2.0 mg/dL and anemia (hemoglobin <11 g/dL), were excluded. Further exclusion criteria were unwillingness to participate.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Plasma CRP level in the control and GIK groups. Timepoint: 0, 6, 24 and 48 hours after admission. Method of measurement: ELIZA kit.	—

Secondary

Measure	Time frame
Plasma CK and CK-MB and cardiac troponin I concentrations. Timepoint: 0, 16 and 24 hours after admission. Method of measurement: ELIZA kit.;ST-segment resolution. Timepoint: 60 minutes after thrombolytic therapy. Method of measurement: ECG.;Pain. Timepoint: 0,1 and 2 hours after thrombolytic therapy. Method of measurement: Interview.;Arrythmia. Timepoint: 7 days after admission. Method of measurement: Cardiac monitoring by a physician.;Re infarction. Timepoint: 7 days after admission. Method of measurement: Recurrent ST elevation of 0.1 mv or recurrent increase in creatinin kinase MB.;Mortality. Timepoint: 7 days after admission. Method of measurement: Any death when cardiac death could not be excluded.;Ejection fraction. Timepoint: 72 hours after admission. Method of measurement: Echocardiography.	—

Measure

Time frame

Plasma CK and CK-MB and cardiac troponin I concentrations. Timepoint: 0, 16 and 24 hours after admission. Method of measurement: ELIZA kit.;ST-segment resolution. Timepoint: 60 minutes after thrombolytic therapy. Method of measurement: ECG.;Pain. Timepoint: 0,1 and 2 hours after thrombolytic therapy. Method of measurement: Interview.;Arrythmia. Timepoint: 7 days after admission. Method of measurement: Cardiac monitoring by a physician.;Re infarction. Timepoint: 7 days after admission. Method of measurement: Recurrent ST elevation of 0.1 mv or recurrent increase in creatinin kinase MB.;Mortality. Timepoint: 7 days after admission. Method of measurement: Any death when cardiac death could not be excluded.;Ejection fraction. Timepoint: 72 hours after admission. Method of measurement: Echocardiography.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Hashemian

Sabzevar university of medical science

medical-school@medsab.ac.ir+98 57 1444 6070

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026